BioArctic AB 2021 AR2
The report outlines BioArctic's financial and operational performance for the fiscal year 2021, highlighting significant progress in its drug development portfolio for central nervous system disorders. Notably, the company's partner, Eisai, initiated a rolling submission to the US FDA for the accelerated approval of lecanemab, a promising drug candidate for early Alzheimer's disease. Additionally, BioArctic expanded its research into ALS with the ND3014 project and continued developing its blood-brain barrier technology. The company also began building a Nordic sales and marketing organization to prepare for the potential commercialization of lecanemab. On the sustainability front, BioArctic aligned its initiatives with the UN Sustainable Development Goals, focusing on sustainable employeeship, resource use, and business practices.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2021
Type: AR2
Pages: 117
Back to company
BioArctic AB
Annual Report
The report outlines BioArctic's financial and operational performance for the fiscal year 2021, highlighting significant progress in its drug development portfolio for central nervous system disorders. Notably, the company's partner, Eisai, initiated a rolling submission to the US FDA for the accelerated approval of lecanemab, a promising drug candidate for early Alzheimer's disease. Additionally, BioArctic expanded its research into ALS with the ND3014 project and continued developing its blood-brain barrier technology. The company also began building a Nordic sales and marketing organization to prepare for the potential commercialization of lecanemab. On the sustainability front, BioArctic aligned its initiatives with the UN Sustainable Development Goals, focusing on sustainable employeeship, resource use, and business practices.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees